| Dr David Ian Weiss, MD | |
|
15 Orleans Dr, Hattiesburg, MS 39402 | |
| (601) 582-7655 | |
| (601) 582-3229 |
| Full Name | Dr David Ian Weiss |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 38 Years |
| Location | 15 Orleans Dr, Hattiesburg, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851431159 | NPI | - | NPPES |
| 0118558 | Medicaid | MS | |
| 660003195 | Other | MS | RR-MCARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 15589 (Mississippi) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arthritis Associates, Pllc | 2668571720 | 3 |
News Archive
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) are pleased to announce that the American College of Cardiology (ACC) journals' portfolio has been expanded with the launch of JACC: Heart Failure.
That state's adoption of the nation's strictest abortion ban - after 12 weeks of pregnancy, when a fetal heartbeat is usually found - is spurring advocates to push similar legislation in Kansas, Kentucky, Mississippi, Ohio, North Dakota and Wyoming. Legal scholars say such laws have little chance of withstanding federal court scrutiny.
Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.
Scientists at the University of Bonn have discovered a previously unknown fruit fly gene that controls the metabolism of fat. Larvae in which this gene is defective lose their entire fat reserves.
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fourth fiscal quarter and full year ended March 31, 2010. The results were highlighted by continued strong U.S. sales growth for Macroplastique and a reduction in operating and net loss compared to the prior year.
› Verified 6 days ago
| Entity Name | Arthritis Associates, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588619167 PECOS PAC ID: 2668571720 Enrollment ID: O20070702000022 |
News Archive
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) are pleased to announce that the American College of Cardiology (ACC) journals' portfolio has been expanded with the launch of JACC: Heart Failure.
That state's adoption of the nation's strictest abortion ban - after 12 weeks of pregnancy, when a fetal heartbeat is usually found - is spurring advocates to push similar legislation in Kansas, Kentucky, Mississippi, Ohio, North Dakota and Wyoming. Legal scholars say such laws have little chance of withstanding federal court scrutiny.
Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.
Scientists at the University of Bonn have discovered a previously unknown fruit fly gene that controls the metabolism of fat. Larvae in which this gene is defective lose their entire fat reserves.
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fourth fiscal quarter and full year ended March 31, 2010. The results were highlighted by continued strong U.S. sales growth for Macroplastique and a reduction in operating and net loss compared to the prior year.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Ian Weiss, MD 15 Orleans Dr, Hattiesburg, MS 39402 Ph: (601) 582-7655 | Dr David Ian Weiss, MD 15 Orleans Dr, Hattiesburg, MS 39402 Ph: (601) 582-7655 |
News Archive
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) are pleased to announce that the American College of Cardiology (ACC) journals' portfolio has been expanded with the launch of JACC: Heart Failure.
That state's adoption of the nation's strictest abortion ban - after 12 weeks of pregnancy, when a fetal heartbeat is usually found - is spurring advocates to push similar legislation in Kansas, Kentucky, Mississippi, Ohio, North Dakota and Wyoming. Legal scholars say such laws have little chance of withstanding federal court scrutiny.
Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.
Scientists at the University of Bonn have discovered a previously unknown fruit fly gene that controls the metabolism of fat. Larvae in which this gene is defective lose their entire fat reserves.
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fourth fiscal quarter and full year ended March 31, 2010. The results were highlighted by continued strong U.S. sales growth for Macroplastique and a reduction in operating and net loss compared to the prior year.
› Verified 6 days ago
Laurie Evans Douglas, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 301 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-261-1700 Fax: 601-288-8290 | |
Dr. Charles Ramsey Mccollum Iii, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-268-5650 Fax: 601-579-5212 | |
Porter Hudson Glover, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-268-5680 Fax: 601-268-5778 | |
Alex Gauthier, Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 601-268-8000 | |
Grettel Rodriguez Garcia, Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 31 Woodstone Dr, Hattiesburg, MS 39402 Phone: 347-342-2441 | |
Ms. Manal Mohammad Abdur Rahman, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 7 Medical Blvd, Hattiesburg, MS 39401 Phone: 601-296-2990 Fax: 601-296-2860 | |
Dr. Vashishtha Patel, DO Rheumatology Medicare: Medicare Enrolled Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 704-733-7499 |